TScan Therapeutics (TCRX) Current Leases (2020 - 2025)
Historic Current Leases for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $6.9 million.
- TScan Therapeutics' Current Leases rose 7711.65% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 7711.65%. This contributed to the annual value of $4.6 million for FY2024, which is 4078.87% up from last year.
- TScan Therapeutics' Current Leases amounted to $6.9 million in Q3 2025, which was up 7711.65% from $6.3 million recorded in Q2 2025.
- TScan Therapeutics' Current Leases' 5-year high stood at $6.9 million during Q3 2025, with a 5-year trough of $1.6 million in Q2 2021.
- In the last 5 years, TScan Therapeutics' Current Leases had a median value of $3.6 million in 2022 and averaged $3.5 million.
- As far as peak fluctuations go, TScan Therapeutics' Current Leases surged by 14378.83% in 2023, and later plummeted by 1413.64% in 2024.
- TScan Therapeutics' Current Leases (Quarter) stood at $1.7 million in 2021, then skyrocketed by 122.96% to $3.7 million in 2022, then decreased by 11.82% to $3.2 million in 2023, then skyrocketed by 40.79% to $4.6 million in 2024, then soared by 51.07% to $6.9 million in 2025.
- Its Current Leases was $6.9 million in Q3 2025, compared to $6.3 million in Q2 2025 and $5.0 million in Q1 2025.